Home / LCTX : AMEX

AI Analysis Fundamentals Valuation Video Analysis News Similar

AI Analysis

How does LCTX make money? Does LCTX have pricing power? What's the Earnings Whisper? Will LCTX profit more as the business scales? What is LCTX's management track record? Is LCTX's current price justified?

Lineage Cell Therapeutics, Inc.

$1.01 -$0.63 (-38.41%)

AMEX · 11 Sep 2026 20:00 UTC

Previous Close

$1.02

Day Range

$1$1.03

Year Range

$1$2.09

Market Cap

251.79M

AVG Volume

1.29M

Trailing/Forward PE

-7.2/-

PEG ratio

-0.13

Dividend Yield

Next Earnings Date

2026-11-05

Primary Exchange

New York Stock Exchange Arca

Revenue (USD)

LCTX Revenue (USD) by year
Period	Revenue (USD)
2025	14.56M
2024	9.5M
2023	8.95M
2022	14.7M
2021	3.9M
2020	773K
2019	1.48M
2018	1.42M
2017	1.79M
2016	2.24M

Net Income (USD)

LCTX Net Income (USD) by year
Period	Net Income (USD)
2025	-63.53M
2024	-18.61M
2023	-21.49M
2022	-26.27M
2021	-43.02M
2020	-20.65M
2019	-11.71M
2018	-45.99M
2017	-19.98M
2016	33.56M

Operating Income (USD)

LCTX Operating Income (USD) by year
Period	Operating Income (USD)
2025	-36.62M
2024	-21.48M
2023	-24.73M
2022	-22.52M
2021	-49.21M
2020	-26.45M
2019	-38.88M
2018	-41.8M
2017	-40.66M
2016	-58.97M

EBITDA (USD)

LCTX EBITDA (USD) by year
Period	EBITDA (USD)
2025	-42.52M
2024	-17.97M
2023	-22.59M
2022	-25.09M
2021	-47.99M
2020	-24.41M
2019	-35.88M
2018	-37.83M
2017	-37.36M
2016	-54.21M

Cash Flows (USD)

LCTX Cash Flows (USD) by year
Period	Cash Flows (USD)
2025	-19.15M
2024	-23.66M
2023	-29.24M
2022	646K
2021	-23.91M
2020	-19.82M
2019	-32.39M
2018	-34.17M
2017	-31.84M
2016	-44.85M

EPS (USD)

LCTX EPS (USD) by year
Period	EPS (USD)
2025	-0.27
2024	-0.1
2023	-0.12
2022	-0.18
2021	-0.26
2020	-0.14
2019	-0.04
2018	-0.35
2017	-0.1
2016	0.32

Expenses (USD)

LCTX Expenses (USD) by year
Period	Expenses (USD)
2025	36.42M
2024	31.03M
2023	33.51M
2022	36.91M
2021	52.48M
2020	27.95M
2019	42.42M
2018	48.97M
2017	45.27M
2016	67.06M

Cash & Debt (USD)

LCTX Cash & Debt (USD) by year
Period	Cash & Debt (USD)
2025	55.78M
2024	47.8M
2023	35.49M
2022	57.88M
2021	58.36M
2020	41.56M
2019	30.72M
2018	30.74M
2017	38.17M
2016	22.71M

Debt ratios

LCTX Debt ratios by year
Period	Debt ratios
2025	0.49
2024	0.4
2023	0.27
2022	0.4
2021	0.38
2020	0.28
2019	0.15
2018	0.15

Margins

LCTX Margins by year
Period	Margins
2025	99%
2024	94.64%
2023	90.54%
2022	95.05%
2021	63.4%
2020	50.19%
2019	72.12%
2018	78.67%
2017	90.62%
2016	82.23%

Return on Capital

LCTX Return on Capital by year
Period	Return on Capital
2025	-146.57%
2024	-24.16%
2023	-34.64%
2022	-36.52%
2021	-47.32%
2020	-21.71%
2019	-10.53%
2018	-49.86%
2017	-12.16%
2016	25.71%

Shares Outstanding

LCTX Shares Outstanding by year
Period	Shares Outstanding
2025	230.12M
2024	200.19M
2023	172.66M
2022	170.01M
2021	167.62M
2020	149.97M
2019	149.06M
2018	126.99M
2017	124.94M
2016	102.78M

Dividends (USD)

LCTX Dividends (USD) by year
Period	Dividends (USD)
2003	0.08

Employee Count

LCTX Employee Count by year
Period	Employee Count
2025	77
2024	77
2023	75
2022	78
2021	61
2020	55
2019	55
2018	79
2017	95
2016	102

Book Value Per Share (USD)

LCTX Book Value Per Share (USD) by year
Period	Book Value Per Share (USD)
2025	0.19
2024	0.38
2023	0.36
2022	0.42
2021	0.54
2020	0.63
2019	0.75
2018	0.73
2017	1.31
2016	1.27

Total Assets (USD)

LCTX Total Assets (USD) by year
Period	Total Assets (USD)
2025	112.58M
2024	113.22M
2023	101.02M
2022	123.66M
2021	174.54M
2020	107.95M
2019	125.48M
2018	101.66M
2017	173.24M
2016	142.57M

PE Ratio

LCTX PE Ratio by year
Period	PE Ratio
Nov 19	3.84
Nov 19	3.79
Oct 19	4.1
Oct 19	4.71
Oct 19	4.53
Oct 19	4.71
Sep 19	4.62
Sep 19	5.15
Sep 19	4.91
Sep 19	4.44
Aug 19	4.5
Aug 19	4.78
Aug 19	4.96
Aug 19	4.43
Aug 19	2.43
Jul 19	2.9
Jul 19	2.57
Jul 19	2.64
Jul 19	2.59
Jun 19	2.57
Jun 19	2.52
Jun 19	2.43
Jun 19	2.34
May 19	2.31
May 19	2.52
May 19	2.73
May 19	2.83
Mar 18	6.62
Mar 18	7.01
Feb 18	6.74
Feb 18	6.39
Feb 18	6.34
Feb 18	7.11
Jan 18	7.11
Jan 18	6.49
Jan 18	6.59
Jan 18	6.17
Dec 17	5.29
Dec 17	5.66
Dec 17	5.73
Dec 17	5.98
Dec 17	6.3
Nov 17	6.52
Nov 17	6.15
Nov 17	6.3
Nov 17	4
Oct 17	3.95
Oct 17	4.39
Oct 17	4.42
Oct 17	4.65
Sep 17	4.72
Sep 17	4.65
Sep 17	4.73
Sep 17	4.7
Sep 17	4.77
Aug 17	4.54
Aug 17	4.22
Aug 17	4.34
Aug 17	2.98
Jul 17	2.99
Jul 17	3.17
Jul 17	3.29
Jul 17	3.34
Jun 17	3.36
Jun 17	3.39
Jun 17	3.19
Jun 17	3.41
Jun 17	3.43
May 17	3.47
May 17	3.29
May 17	3.41
May 17	9.49
Apr 17	10.41
Apr 17	9.59
Apr 17	9.98
Apr 17	10.32
Mar 17	10.57
Mar 17	13
Mar 17	14.63
Mar 17	12.75
Mar 17	13.69
Feb 17	13.44
Feb 17	12.1
Feb 17	11.73
Feb 17	12.71
Jan 17	12.95
Jan 17	13.53
Jan 17	14.1
Jan 17	15.15
Dec 16	14.71
Dec 16	15.48
Dec 16	15.4
Dec 16	13.53
Dec 16	12.95
Nov 16	14.75
Nov 16	14.87
Nov 16	14.67
Nov 16	12.83

Free Cash Flow Yield

LCTX Free Cash Flow Yield by year
Period	Free Cash Flow Yield
Sep 26	-9.5%
Sep 26	-8.88%
Aug 26	-8.64%
Aug 26	-8.88%
Aug 26	-8.97%
Aug 26	-8.72%
Jul 26	-8.43%
Jul 26	-8.84%
Jul 26	-7.85%
Jul 26	-7.11%
Jul 26	-6.74%
Jun 26	-7.11%
Jun 26	-7.52%
Jun 26	-7.17%
Jun 26	-7.65%
May 26	-6.84%
May 26	-7%
May 26	-7.28%
May 26	-6.08%
May 26	-5.44%
Apr 26	-5.37%
Apr 26	-4.87%
Apr 26	-5.62%
Apr 26	-5.3%
Mar 26	-5.59%
Mar 26	-5.74%
Mar 26	-5.17%
Mar 26	-4.5%
Feb 26	-4.75%
Feb 26	-5.04%
Feb 26	-5.49%
Feb 26	-5.37%
Jan 26	-6.16%
Jan 26	-5.67%
Jan 26	-5.37%
Jan 26	-5.33%
Jan 26	-5.56%
Dec 25	-5.53%
Dec 25	-5.43%
Dec 25	-5.49%
Dec 25	-5.3%
Nov 25	-5.18%
Nov 25	-5.24%
Nov 25	-4.85%
Nov 25	-5.18%
Oct 25	-5.28%
Oct 25	-5.96%
Oct 25	-6.14%
Oct 25	-6.11%
Oct 25	-6%
Sep 25	-5.93%
Sep 25	-6.62%
Sep 25	-7.56%
Sep 25	-8.31%
Aug 25	-8.66%
Aug 25	-8.45%
Aug 25	-8.45%
Aug 25	-10.25%
Aug 25	-10.25%
Jul 25	-8.93%
Jul 25	-10.51%
Jul 25	-9.8%
Jul 25	-9.99%
Jun 25	-10.79%
Jun 25	-10.63%
Jun 25	-12.45%
Jun 25	-14.95%
May 25	-15.19%
May 25	-14.45%
May 25	-21.8%
May 25	-26.86%
May 25	-24.08%
Apr 25	-24.12%
Apr 25	-28.82%
Apr 25	-25.15%
Apr 25	-27.33%
Mar 25	-24.02%
Mar 25	-23.33%
Mar 25	-22.73%
Mar 25	-23.24%
Feb 25	-21.74%
Feb 25	-18.06%
Feb 25	-17.57%
Feb 25	-18.22%
Jan 25	-20.33%
Jan 25	-19.2%
Jan 25	-20.79%
Jan 25	-21.05%
Jan 25	-20.69%
Dec 24	-24.57%
Dec 24	-21.88%
Dec 24	-24.13%
Dec 24	-20.84%
Nov 24	-21.35%
Nov 24	-24.23%
Nov 24	-14.12%
Nov 24	-12.8%
Nov 24	-14.5%
Oct 24	-14.06%
Oct 24	-13.04%

Price to Sales

LCTX Price to Sales by year
Period	Price to Sales
Sep 26	19.26
Sep 26	20.6
Aug 26	21.17
Aug 26	20.6
Aug 26	20.41
Aug 26	20.98
Jul 26	17.91
Jul 26	17.08
Jul 26	19.23
Jul 26	21.22
Jul 26	22.38
Jun 26	21.22
Jun 26	20.06
Jun 26	21.06
Jun 26	19.73
May 26	22.05
May 26	21.55
May 26	20.72
May 26	21.66
May 26	24.19
Apr 26	24.5
Apr 26	27.03
Apr 26	23.4
Apr 26	24.82
Mar 26	23.56
Mar 26	22.92
Mar 26	25.45
Mar 26	29.25
Feb 26	40.62
Feb 26	38.3
Feb 26	35.12
Feb 26	35.97
Jan 26	31.31
Jan 26	34.07
Jan 26	35.97
Jan 26	36.18
Jan 26	34.7
Dec 25	34.91
Dec 25	35.55
Dec 25	35.12
Dec 25	36.39
Nov 25	37.24
Nov 25	36.82
Nov 25	39.78
Nov 25	37.24
Oct 25	40.17
Oct 25	35.57
Oct 25	34.52
Oct 25	34.73
Oct 25	35.36
Sep 25	35.78
Sep 25	32.01
Sep 25	28.04
Sep 25	25.53
Aug 25	24.48
Aug 25	25.11
Aug 25	25.11
Aug 25	23.28
Aug 25	23.31
Jul 25	26.73
Jul 25	22.73
Jul 25	24.36
Jul 25	23.89
Jun 25	22.12
Jun 25	22.47
Jun 25	19.17
Jun 25	15.97
May 25	15.72
May 25	16.53
May 25	10.95
May 25	9.27
May 25	10.34
Apr 25	10.33
Apr 25	8.64
Apr 25	9.9
Apr 25	9.11
Mar 25	10.37
Mar 25	10.67
Mar 25	10.96
Mar 25	11.38
Feb 25	12.16
Feb 25	14.64
Feb 25	15.05
Feb 25	14.52
Jan 25	13.01
Jan 25	13.77
Jan 25	12.72
Jan 25	12.56
Jan 25	12.78
Dec 24	10.76
Dec 24	12.09
Dec 24	10.96
Dec 24	12.69
Nov 24	12.39
Nov 24	10.91
Nov 24	18.72
Nov 24	28.2
Nov 24	24.9
Oct 24	25.67
Oct 24	27.69

Price/Operating Cashflow

LCTX Price/Operating Cashflow by year
Period	Price/Operating Cashflow
May 23	229.57
Apr 23	218.33
Apr 23	215.12
Apr 23	226.36
Apr 23	219.94
Mar 23	240.81
Mar 23	234.39
Mar 23	226.36
Mar 23	229.57
Mar 23	68.13
Feb 23	59.37
Feb 23	67.16
Feb 23	65.7
Feb 23	69.1
Jan 23	68.13
Jan 23	72.51
Jan 23	73.97
Jan 23	64.24
Dec 22	56.94
Dec 22	53.04
Dec 22	62.29
Dec 22	59.37
Dec 22	72.99
Nov 22	69.1
Nov 22	70.08
Nov 22	70.08
Nov 22	53.75
Oct 22	51.69
Oct 22	44.72
Oct 22	43.9
Oct 22	49.23
Sep 22	46.36
Sep 22	48.41
Sep 22	52.93
Sep 22	53.34
Sep 22	57.03
Aug 22	59.49
Aug 22	59.49
Aug 22	64.41
Aug 22	50.3
Jul 22	48.24
Jul 22	46.77
Jul 22	48.24
Jul 22	50.6
Jul 22	46.18
Jun 22	40.3
Jun 22	40.01
Jun 22	41.18
Jun 22	41.18
May 22	38.54
May 22	36.77
May 22	32.95

Price to Book

LCTX Price to Book by year
Period	Price to Book
Sep 26	4.21
Sep 26	4.51
Aug 26	4.63
Aug 26	4.51
Aug 26	4.46
Aug 26	4.59
Jul 26	5.02
Jul 26	4.79
Jul 26	5.39
Jul 26	5.95
Jul 26	6.28
Jun 26	5.95
Jun 26	5.63
Jun 26	5.91
Jun 26	5.53
May 26	6.18
May 26	6.04
May 26	5.81
May 26	7.27
May 26	8.12
Apr 26	8.23
Apr 26	9.08
Apr 26	7.86
Apr 26	8.33
Mar 26	7.91
Mar 26	7.7
Mar 26	8.55
Mar 26	9.82
Feb 26	21.13
Feb 26	19.92
Feb 26	18.27
Feb 26	18.71
Jan 26	16.29
Jan 26	17.72
Jan 26	18.71
Jan 26	18.82
Jan 26	18.05
Dec 25	18.16
Dec 25	18.49
Dec 25	18.27
Dec 25	18.93
Nov 25	19.37
Nov 25	19.15
Nov 25	20.69
Nov 25	19.37
Oct 25	9.31
Oct 25	8.24
Oct 25	8
Oct 25	8.05
Oct 25	8.19
Sep 25	8.29
Sep 25	7.42
Sep 25	6.5
Sep 25	5.91
Aug 25	5.67
Aug 25	5.82
Aug 25	5.82
Aug 25	2.87
Aug 25	2.87
Jul 25	3.29
Jul 25	2.8
Jul 25	3
Jul 25	2.94
Jun 25	2.72
Jun 25	2.77
Jun 25	2.36
Jun 25	1.97
May 25	1.93
May 25	2.03
May 25	1.35
May 25	1.14
May 25	1.28
Apr 25	1.27
Apr 25	1.07
Apr 25	1.22
Apr 25	1.12
Mar 25	1.28
Mar 25	1.32
Mar 25	1.35
Mar 25	1.53
Feb 25	1.64
Feb 25	1.97
Feb 25	2.03
Feb 25	1.95
Jan 25	1.75
Jan 25	1.85
Jan 25	1.71
Jan 25	1.69
Jan 25	1.72
Dec 24	1.45
Dec 24	1.63
Dec 24	1.47
Dec 24	1.71
Nov 24	1.67
Nov 24	1.47
Nov 24	2.52
Nov 24	2.61
Nov 24	2.3
Oct 24	2.37
Oct 24	2.56

No video analysis for this stock yet. Request one from our team.

News: LCTX

businesswire.com · 8 Sep 2026

Lineage Cell Therapeutics Announces Issuance of Patent Underlying Its AlloSCOPE™ 5D Manufacturing Platform

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--AlloSCOPE 5D Patent Release.

marketbeat.com · 9 Aug 2026

Lineage Cell Therapeutics Q2 Earnings Call Highlights

Lineage Cell Therapeutics NYSEAMERICAN: LCTX outlined progress across its cell-therapy pipeline during its second-quarter 2026 earnings call, highlighting preclinical advances in corneal disease, Type 1 diabetes and hearing loss programs while Roche and Genentech continue surgical-delivery optimization work for its lead OpRegen program.

seekingalpha.com · 7 Aug 2026

Lineage Cell Therapeutics, Inc. (LCTX) Q2 2026 Earnings Call Transcript

zacks.com · 6 Aug 2026

Lineage Cell (LCTX) Reports Q2 Loss, Lags Revenue Estimates

Lineage Cell (LCTX) came out with a quarterly loss of $0.03 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.01 per share a year ago.

businesswire.com · 6 Aug 2026

Lineage Cell Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Q2 2026 Earnings Release.

marketbeat.com · 14 Jul 2026

Lineage Cell Therapeutics Maps COR1 Path With ‘Thaw and Inject' Cell Therapy Plan

Lineage Cell Therapeutics NYSEAMERICAN: LCTX used a conference call to outline its manufacturing strategy and development plans for COR1, a wholly owned preclinical cell transplant program being developed as a potential treatment for corneal endothelial disease.

seekingalpha.com · 13 Jul 2026

Lineage Cell Therapeutics, Inc. (LCTX) Discusses COR1 Cell Transplant Program and Manufacturing Strategy for Corneal Endothelial Disease Transcript

businesswire.com · 13 Jul 2026

Lineage Provides Update on COR1 Cell Therapy Program for Corneal Endothelial Disease

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel, allogeneic, “off the shelf”, cell therapies for serious medical conditions, today provided an update on COR1, the Company's allogeneic corneal endothelial cell (CEnC) transplant program, in preclinical development for the treatment of corneal endothelial disease. With COR1, Lineage is deploying its ophthalmology and cell manufacturing expert.